HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 2005-0654v1 24/5/1409    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sotiropoulou, P. A. Articles by Papamichail, M. Search for Related Content PubMed PubMed Citation Articles by Sotiropoulou, P. A. Articles by Papamichail, M.

LETTER TO THE EDITOR

Cell Culture Medium Composition and Translational Adult Bone Marrow-Derived Stem Cell Research

Cancer Immunology and Immunotherapy Center, Saint Savas Hospital, Athens, Greece

Correspondence: Panagiota A. Sotiropoulou, Ph.D., Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 171, Alexandras Avenue, 115 22 Athens, Greece. Telephone: +30-210-6409462; Fax: +30-210-6409516; e-mail: sotiropoulou{at}ciic.gr

Received December 28, 2005; accepted for publication January 18, 2006.
The use of fetal calf serum (FCS) for the culture of cells to be used in clinical trials raises potential hazards that cannot be neglected, but this is a regulatory issue. However, as specifically regards the isolation and expansion of human mesenchymal stem cells (MSCs), unfortunately serum-free media have not yet been defined. The alternative of using autologous serum is feasible only for the minority of clinical protocols involving low numbers of MSCs, because a minimum concentration of 10% in the culture medium is required. Besides, because allogeneic serum results in MSC growth arrest and death, use of pooled human serum does not represent an alternative. Finally, vast numbers of MSCs cultured in FCS-containing media have already been used in many clinical trials targeting a variety of disorders, without any significant side effects, including ventricular arrhythmia.

This article has been cited by other articles:

				N. Sakamoto, K. Tsuji, L. M. Muul, A. M. Lawler, E. F. Petricoin, F. Candotti, J. A. Metcalf, J. A. Tavel, H. C. Lane, W. J. Urba, et al. Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans Blood, July 15, 2007; 110(2): 501 - 508. [Abstract] [Full Text] [PDF]

				F. Mannello and G. A. Tonti Concise Review: No Breakthroughs for Human Mesenchymal and Embryonic Stem Cell Culture: Conditioned Medium, Feeder Layer, or Feeder-Free; Medium with Fetal Calf Serum, Human Serum, or Enriched Plasma; Serum-Free, Serum Replacement Nonconditioned Medium, or Ad Hoc Formula? All That Glitters Is Not Gold! Stem Cells, July 1, 2007; 25(7): 1603 - 1609. [Abstract] [Full Text] [PDF]

				A. Kocaoemer, S. Kern, H. Kluter, and K. Bieback Human AB Serum and Thrombin-Activated Platelet-Rich Plasma Are Suitable Alternatives to Fetal Calf Serum for the Expansion of Mesenchymal Stem Cells from Adipose Tissue Stem Cells, May 1, 2007; 25(5): 1270 - 1278. [Abstract] [Full Text] [PDF]

				D. G. Katritsis, P. Sotiropoulou, E. Giazitzoglou, E. Karvouni, and M. Papamichail Electrophysiological effects of intracoronary transplantation of autologous mesenchymal and endothelial progenitor cells Europace, March 1, 2007; 9(3): 167 - 171. [Abstract] [Full Text] [PDF]

				M. G. Berger, R. Veyrat-Masson, C. Rapatel, S. Descamps, J. Chassagne, and N. Boiret-Dupre Cell Culture Medium Composition and Translational Adult Bone Marrow-Derived Stem Cell Research Stem Cells, December 1, 2006; 24(12): 2888 - 2890. [Abstract] [Full Text] [PDF]